| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,300 | ₹5.8 0% | 1250% |
| - | - | 4,400 | ₹5.8 0% | 1250% |
| - | - | 4,600 | ₹15.95 6.33% | 875133.33% |
| - | - | 4,650 | ₹20 0% | 3,1250% |
| - | - | 4,700 | ₹21.8 -0.45% | 1,750100% |
| - | - | 4,750 | ₹29.75 24.73% | 1,000-42.85% |
| - | - | 4,800 | ₹33.1 13.55% | 5,87511.90% |
| - | - | 4,850 | ₹36.95 -3.01% | 8750% |
| - | - | 4,900 | ₹44.4 0% | 3750% |
| - | - | 4,950 | ₹57.85 -6.69% | 2,12530.76% |
| 750200% | ₹235 -21.61% | 5,000 | ₹70.45 16.25% | 9,62518.46% |
| - | - | 5,050 | ₹56.75 0% | 1,7500% |
| 3,25030% | ₹179.8 -28% | 5,100 | ₹105 24.48% | 13,25039.47% |
| 1,00060% | ₹148.35 -31.62% | 5,150 | ₹121.5 20.29% | 5,750119.04% |
| 14,37543.75% | ₹123.5 -25.84% | 5,200 | ₹149.7 19.18% | 30,7508.84% |
| 3,6252800% | ₹101 -26.62% | 5,250 | - | - |
| 13,00015.55% | ₹82 -28.57% | 5,300 | ₹207.4 16.97% | 6,50010.63% |
| 6250% | ₹92.15 0.54% | 5,350 | - | - |
| 22,00054.38% | ₹49.5 -35.5% | 5,400 | ₹229.05 -1.39% | 4,5000% |
| 1,8750% | ₹42 -42.46% | 5,450 | ₹235.25 0% | 7500% |
| 8,12541.30% | ₹31.6 -37.05% | 5,500 | ₹372.85 0% | 15,3750% |
| 2,5000% | ₹38.15 1.46% | 5,550 | - | - |
| 8,62516.94% | ₹19 -38.8% | 5,600 | ₹314.95 0% | 1250% |
| 3750% | ₹64.5 0% | 5,650 | - | - |
| 5,87527.02% | ₹11 -44.16% | 5,700 | - | - |
| 4,250-5.55% | ₹8.45 -45.65% | 5,750 | - | - |
| 2,6250% | ₹10 -23.07% | 5,800 | ₹280.55 0% | 2500% |
| 1,62518.18% | ₹5.6 -42.85% | 5,850 | - | - |
| 1,8757.14% | ₹4.45 -29.36% | 5,950 | - | - |
| 5,50029.41% | ₹3.65 -39.16% | 6,000 | ₹841.35 0% | 00% |
| 4,5000% | ₹4.3 0% | 6,050 | - | - |
| 2500% | ₹44.1 0% | 6,100 | ₹808.15 0% | 3750% |
| - | - | 6,500 | ₹1,020 0% | 1250% |
| 00% | ₹5 0% | 6,600 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
